NVCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novocure Ltd (NVCR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are bearish, options sentiment is mixed, and financial performance shows declining profitability despite revenue growth. While there is a positive catalyst in the form of FDA approval for a new treatment, the overall sentiment and lack of strong trading signals suggest holding off on an investment for now.
The technical indicators for NVCR are bearish. The MACD histogram is negative and contracting, RSI is neutral at 40.2, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 11.901, with resistance at 13.521.
FDA approval of Optune Pax for treating locally advanced pancreatic cancer, which could drive future revenue growth.
Declining net income (-62.84% YoY), EPS (-63.93% YoY), and gross margin (-4.33% YoY) in the latest quarter. Additionally, bearish technical trends and mixed options sentiment weigh on the stock.
In Q4 2025, revenue increased by 8.11% YoY to $174.35M. However, net income dropped significantly to -$24.5M (-62.84% YoY), EPS fell to -0.22 (-63.93% YoY), and gross margin declined to 75.82% (-4.33% YoY).
Analysts are mixed. H.C. Wainwright raised the price target to $47 and maintained a Buy rating following FDA approval news. Evercore ISI lowered the price target to $20 but kept an Outperform rating, citing sector rotation and potential risks from ACA and Medicare changes.
